No pharmacokinetic interaction between paliperidone extended-release tablets and trimethoprim in healthy subjects

Human Psychopharmacology

Volumn 24, Issue 7, 2009, Pages 532-539

  Thyssen, An ^a   Cleton, Adriaan ^a,c   Talluri, Krishna ^b,d   Leempoels, Jos ^a   Janssens, Luc ^a   Boom, Sandra ^a,c   Eerdekens, Marielle ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^b JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^c Pharma Plus ^*  (Netherlands)

^d Talecris Biotherapeutics Inc   (United States)

Author keywords

Drug interaction; Paliperidone; Pharmacokinetics; Trimethoprim

Indexed keywords

DRUG METABOLITE; PALIPERIDONE; R 078543; R 078544; TRIMETHOPRIM; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; CREATININE CLEARANCE; CROSSOVER PROCEDURE; DIARRHEA; DIZZINESS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EXCRETION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; ENANTIOMER; EVENING DOSAGE; FATIGUE; FLATULENCE; HALF LIFE TIME; HUMAN; HUMAN EXPERIMENT; KIDNEY CLEARANCE; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; NORMAL HUMAN; ORTHOSTATIC HYPOTENSION; PLASMA CONCENTRATION-TIME CURVE; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SOMNOLENCE; XEROSTOMIA;

ADULT; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; AREA UNDER CURVE; CROSS-OVER STUDIES; DRUG ADMINISTRATION SCHEDULE; DRUG DELIVERY SYSTEMS; DRUG INTERACTIONS; ELECTROCARDIOGRAPHY; FOLIC ACID ANTAGONISTS; HEART RATE; HUMANS; ISOXAZOLES; MALE; MIDDLE AGED; PYRIMIDINES; SINGLE-BLIND METHOD; TIME FACTORS; TRIMETHOPRIM; YOUNG ADULT;

EID: 72849121553     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.1049     Document Type: Article

References (18)

1. Annaert P, Steemans K, Mannens G, et al., 2005. In vitro study on transepithelial transport of the psychotropic compound paliperidone (PAL) across Caco-2 monolayers. Drug Metab Rev 37 (Suppl 1): 15.
2. Chatton JY, Munafo A, Chave JP, et al., 1992. Trimethoprim, alone or in combination with sulphamethoxazole, decreases the renal excretion of zidovudine and its glucuronide. Br J Clin Pharmacol 34: 551-554.
3. De Meulder M, Remmerie B, de Vries R, et al., 2008. Validated LC-MS/MS method for the determination of risperidone and the enantiomers of 9- hydroxyrisperidone in human plasma and urine. J Chrom B 870: 8-16.
4. Du Buske, LM. 2005. The role of P-glycoprotein and organic anion-transporting polypeptides in drug interactions. Drug Safety 28: 789-801.
5. Hellerstein S, Berenbom M, Alon US, Warady BA. 1998. Creatinine clearance following cimetidine for estimation of glomerular filtration rate. Pediatr Nephrol 12: 49-54. (Pubitemid 28165781)
6. Karlsson P, Dencker E, Nyberg S, et al., 2006. Pharmacokinetics, dopamine D2 and serotonin 5-HT2A receptor occupancy and safety profile of paliperidone extended-release in healthy subjects. Schizophr Res 81: 85-86.
7. Kastrup J, Petersen P, Bartram R, Hansen JM. 1985. The effect of trimethoprim on serum creatinine. Br J Urol 57: 265-268.
8. Mannens G, Meuldermans W, Snoeck E, Heykants J. 1994. Plasma protein binding of risperidone and its distribution in blood. Psychopharmacology (Berl) 114: 566-572. (Pubitemid 24152136)
9. Megens AA, Awouters FHL. 1994. In vivo pharmacological profile of 9-hydroxyrisperidone the major metabolite of the novel antipsychotic risperidone. Drug Dev Res 33: 399-412.
10. Niemi M, Backman JT, Neuvonen PJ. 2004. Effects of trimethoprim and rifampin on the pharmacokinetics of the cytochrome P450 2C8 substrate rosiglitazone. Clin Pharmacol Ther 76: 239-249. (Pubitemid 39221798)
11. Ohno Y, Hisaka A, Suzuki H. 2007. General framework for the quantitative prediction of CYP3A4-mediated oral drug interactions based on the AUC increase by coadministration of standard drugs. Clin Pharmacokinet 46: 681-696. (Pubitemid 47204854)
12. Rossenu S, Cleton A, Rusch S, et al., 2006. Extended-release formulation of paliperidone shows dose-proportional pharmacokinetics. AAPS J 8 (Suppl 2): T3123.
13. Rossenu S, Vermeulen A, Cleton A, et al., 2006. A pharmacokinetic model to document the interconversion between the enantiomers of paliperidone. Clin Pharmacol Ther 79: PII-72.
14. Schotte A, Janssen PF, Gommeren W, et al., 1996. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl) 124: 57-73.
15. Tanigawara Y. 2000. Role of P-glycoprotein in drug disposition. Ther Drug Monit 22: 137-140.
16. Vermeir M, Naessens I, Remmerie B, et al., 2008. Absorption, metabolism, and excretion of paliperidone, a new monoaminergic antagonist, in humans. Drug Metab Dispos 36: 769-779.
17. Yang LP, Plosker GL. 2007. Paliperidone extended release. CNS Drugs 21: 417-425; discussion. 26-27.
18. Yasui-Furukori N, Uno T, Sugawara K, Tateishi T. 2005. Different effects of three transporting inhibitors, verapamil, cimetidine, and probenecid, on fexofenadine pharmacokinetics. Clin Pharmacol Ther 77: 17-23. (Pubitemid 40075385)